关于在宫缩抑制剂临床应用中引入用药频度及使用强度分析指标的研究

Introduction of DDDs and AUD in the Utilization of Tocolytics

目的:指导宫缩抑制剂的临床规范用药。方法:制定各宫缩抑制剂的限定日剂量(DDD),利用医院信息管理系统中的阳光用药模块,参照抗菌药物使用强度(AUD)计算的操作原理,设置相应参数。汇总我院2009-2012年宫缩抑制剂的用药频度(DDDs)和AUD。结果:利托君、阿托西班、硫酸镁和硝苯地平的DDD分别为40 mg、165 mg、7.5 g和80 mg。我院硝苯地平和阿托西班的DDDs远低于硫酸镁和利托君,单一患者AUD差异大,全院AUD逐年上升。结论:DDDs和AUD等分析单位的引入,有助于宫缩抑制剂临床合理应用水平的提高,并保障患者合法权益和用药安全,但亟需各级卫生部门制订可供参考的合理AUD范围。

OBJECTIVE ： To promote rational use oftoeolytics in the clinic. METHODS ： The defined daily dose （DDD） oftocolytic agents were worked out. The DDDs and AUD from 2009 to 2012 were summarized by Hospital Information System and referring to the calculation principle of antibacterial agents use density. RESULTS ： DDD of ritodrine, atosiban, magnesium sulfate and nifedipine were 40 mg, 165 mg, 7.5 g and 80 mg, respectively. In our hospital, the DDDs of nifedipine and atosiban were far below those of ritodrine and magnesium sulfate. The AUD values were highly individual, and the AUD values of whole hospital were on rise year by year. CON- CLUSIONS： The introduction of DDDs and AUD is beneficial to promote rational drug use of tocolytic and ensure the lawful right and in- terests and security of pregnant women. However, the clinical rational range of AUD is in urgent need of development by official mission.